View Patent here
Raymond James Maintains Outperform on CSX, Raises Price Target to $41
Raymond James analyst Patrick Tyler Brown maintains CSX (NASDAQ:CSX) with a Outperform and raises the price target from $38 to $41.
Related Posts
Viveve Medical Q1 EPS $(0.67), Inline, Sales $1.60M Miss $1.73M Estimate
Viveve Medical (NASDAQ:VIVE) reported quarterly losses of $(0.67) per share which met the analyst consensus estimate. This is a 16.25 percent increase over losses of $(0.80) per share from the same period last year. The
Sidus Space Reports Successful Completion Of LizzieSat Preliminary Design Review
Sidus Space, Inc. (NASDAQ:SIDU), a Space-as-a-Service satellite company focused on commercial satellite design, manufacture, launch, and data collection is pleased to announce the successful completion of the
If You Invested $1,000 When Elon Musk Said Tesla’s Stock Price Was Too High, Here’s How Much You’d Have Now
Tesla Inc (NASDAQ: TSLA) CEO Elon Musk bought social media platform Twitter in 2022, a place where he likes to share